BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

Shire sets its peer group

With a $1.6 billion breakup fee in hand from erstwhile merger partner AbbVie Inc. (NYSE:ABBV), Shire plc (LSE:SHP; NASDAQ:SHPG) on Friday reiterated its prospects as an independent company focused on rare and specialty diseases, comparing its business development strategy to the paths taken by Gilead Sciences Inc. (NASDAQ:GILD), Biogen Idec Inc. (NASDAQ:BIIB) and Celgene Corp. (NASDAQ:CELG). more >>

   COMPANY NEWS

Unlike FDA panel, CHMP backs AZ's olaparib

EMA's CHMP recommended marketing authorization of Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) as maintenance treatment of platinum-sensitive relapsed ovarian, fallopian tube or peritoneal cancer in patients with germline breast cancer early onset (BRCA) mutations who are responding to platinum-based chemotherapy. If approved, the therapy would be the first poly(ADP-ribose) polymerase (PARP) inhibitor available in the indication. more >>

CHMP wants more warnings for Ariad's Iclusig

EMA's CHMP recommended stronger warnings concerning risks of blood clots and arterial blockage with use of leukemia drug Iclusig ponatinib from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA). CHMP's opinion endorses a similar recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month. more >>

CHMP recommends Clinuvel's Scenesse

EMA's CHMP recommended marketing authorization under exceptional circumstances for Scenesse afamelanotide from Clinuvel Pharmaceuticals Ltd. (ASX:CUV; Xetra:UR9) to treat phototoxicity in patients with erythropoietic protoporphyria (EPP), a disorder characterized by extreme sensitivity to sunlight. more >>

Baxter's Rixubis gets CHMP nod for hemophilia B

EMA's CHMP recommended marketing authorization of Rixubis (BAX 326) from Baxter International Inc. (NYSE:BAX) to treat and prevent bleeding in patients with hemophilia B. Approval will include a pharmacovigilance plan. more >>

Venture Tracks

PureTech Ventures (Boston, Mass.) named Robert Horvitz, Joi Ito and Raju Kucherlapati as senior partners. more >>

   FINANCIAL NEWS

Coherus sets IPO terms

Biosimilars developer Coherus Biosciences Inc. (Redwood City, Calif.) set terms for its IPO on NASDAQ and plans to sell 6.3 million shares at $12-$15. At $13.50 Coherus would raise $85 million and be valued at $432.7 million. JPMorgan; Credit Suisse; and Cowen are underwriters. more >>

Angion withdraws IPO

Angion Biomedica Corp. (Uniondale, N.Y.) withdrew its proposed IPO on NASDAQ, citing market conditions. In June, the company amended its IPO to sell 2.7 million shares at $10-$12. At $11, the company would have raised $30 million and been valued at $73.1 million. In April, Angion filed to raise up to $34.5 million. Aegis Capital was the sole underwriter. more >>

Advertisement

SCIBX: SCIENCE-BUSINESS EXCHANGE

SCIBX: SCIENCE-BUSINESS EXCHANGE
COVER STORY

Diagnosing resistance

The frontier for combating antibiotic resistance is now in developing fast, sensitive and versatile diagnostics that can improve treatment and optimize clinical trials.

TARGETS & MECHANISMS

Branching out in pancreatic cancer

Changes in circulating levels of branched-chain amino acids detectable 2-5 years before the onset of pancreatic cancer could lead to diagnostic markers for the indication.

TOOLS

Programmable sensitivity

CRISPR-based antimicrobials can resensitize antibiotic-resistant bacteria by targeting specific resistance genes and could add new tools for combating resistance.

THERAPEUTICS

This Week in Therapeutics

Inhibiting SAT1 to overcome resistance to radiotherapy in GBM; treating obesity and diabetes with a Hoodia gordonii herb-derived compound; altering the intestinal microbiome to treat osteomyelitis; and more...

TECHNIQUES

This Week in Techniques

An anthrax component-based system for intracellular delivery of small molecule antibody mimics; a dual-modality immuno-SPECT/NIRF probe to guide surgical resection of prostate tumors; single-cell immune signatures to predict clinical recovery from surgery; and more...

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement